THE agenda for the November
meeting of the Pharmaceutical
Advisory Committee (PBAC) is now
available for scrutiny by interested
stakeholders and input is invited.
Some of the drugs being
considered for changes to their
status include oxycodone with
nalaxone for severe disabling pain,
omalizumab for urticaria, irinotecan
for metastatic pancreatic cancer,
Edoxaban anticoagulant and many
more.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.